BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals is a U.S. biotechnology company focused on developing and commercializing targeted medicines for rare diseases. Its scientific capabilities emphasize small-molecule discovery and pharmacological approaches selected for specific disease mechanisms. BioCryst is particularly associated with hereditary angioedema and maintains research interests in additional rare conditions. The company operates from Research Triangle Park, North Carolina, and its common shares are listed on Nasdaq under BCRX. BioCryst combines medicinal chemistry and biological research with development and commercialization capabilities. Its focus on rare diseases shapes its approach to therapeutic discovery, clinical development and interactions with specialized patient communities.
Company at a glance
Corporate information
- Company entity
- BioCryst Pharmaceuticals, Inc.
- Headquarters / principal office
- United States
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.biocryst.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Nasdaq: BCRX
structure-guided small molecules · oral therapeutics
rare diseases · hereditary angioedema
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
BioCryst Pharmaceuticals is a U.S. biotechnology company focused on developing and commercializing targeted medicines for rare diseases. Its scientific capabilities emphasize small-molecule discovery and pharmacological approaches selected for specific disease mechanisms. BioCryst is particularly associated with hereditary angioedema and maintains research interests in additional rare conditions. The company operates from Research Triangle Park, North Carolina, and its common shares are listed on Nasdaq under BCRX. BioCryst combines medicinal chemistry and biological research with development and commercialization capabilities. Its focus on rare diseases shapes its approach to therapeutic discovery, clinical development and interactions with specialized patient communities.
Business, technology & evidence
- SecuritiesNasdaq: BCRX
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · BioCryst Pharmaceuticals, Inc. ↗BioCryst Pharmaceuticals, Inc. ·
- Official issuer and R&D disclosure · BioCryst Pharmaceuticals, Inc. ↗BioCryst Pharmaceuticals, Inc. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.